All In Biotech

Drug Trial Radar · NCT07491445

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Mar 9, 2026

Primary completion

Apr 2028

Study completion Mar 2029

Sponsor

Lead sponsor
Revolution Medicines, Inc.Industry
Sponsor type
Industry
First posted
Mar 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

Conditions

  • Pancreatic Cancer
  • Pancreatic Cancer Metastatic
  • PDAC
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Pancreatic Adenocarcinoma Metastatic
  • Pancreatic Adenocarcinoma
  • Pancreatic Adenosquamous Carcinoma

Interventions

  • daraxonrasibDrug

    oral tablets

  • gemcitabineDrug

    intravenous (IV) infusion

  • nab-paclitaxelDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS) as assessed by blinded independent central review (BICR)Time frame: Up to approximately 2 years
  2. Overall survival (OS)Time frame: Up to approximately 2 years

Locations

106 sites in 21 countries. Site status is shown where the registry gives one.

  • Mayo Clinic - Scottsdale

    Phoenix, Arizona · Active not recruiting

  • Honor Health Research Institute

    Scottsdale, Arizona · Active not recruiting

  • University of California Los Angeles Health - Hematology/Oncology

    Los Angeles, California · Active not recruiting

  • University of California San Francisco

    San Francisco, California · Active not recruiting

  • Mayo Clinic Cancer Center- Florida

    Jacksonville, Florida · Active not recruiting

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida · Active not recruiting

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland · Active not recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Active not recruiting

  • Henry Ford Health System

    Detroit, Michigan · Active not recruiting

  • Mayo Clinic Cancer Center- Rochester

    Rochester, Minnesota · Active not recruiting

  • Comprehensive Cancer Centers of Nevada

    Henderson, Nevada · Active not recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Active not recruiting

  • Duke University Medical Center

    Durham, North Carolina · Active not recruiting

  • University of Cincinnati Cancer Center

    Cincinnati, Ohio · Active not recruiting

  • Taylor Cancer Research Center

    Maumee, Ohio · Active not recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Active not recruiting

  • SCRI - Texas Oncology Dallas

    Dallas, Texas · Active not recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Active not recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Active not recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Active not recruiting

  • Virginia Mason Medical Center

    Seattle, Washington · Active not recruiting

  • St. George Hospital

    Kogarah, New South Wales, Australia · Recruiting

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia · Recruiting

  • GenesisCare St Leonards

    Saint Leonards, New South Wales, Australia · Recruiting

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia · Recruiting

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia · Recruiting

  • Epworth HealthCare

    East Melbourne, Victoria, Australia · Recruiting

  • Austin Health, Olivia Newton-John Cancer Research & Wellness Centre

    Heidelberg, Victoria, Australia · Recruiting

  • Krankenhaus Barmherzige Schwestern Linz

    Linz, Austria · Recruiting

  • Krankenhaus der Barmherzigen Brüder Wien-Klinisch wissenschaftliche Studien

    Vienna, Austria · Recruiting

  • Institut Jules Bordet

    Anderlecht, Belgium · Recruiting

  • Imeldaziekenhuis

    Bonheiden, Belgium · Recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Recruiting

  • Universitair Ziekenhuis Brussel

    Jette, Belgium · Recruiting

  • UZ Leuven (Univ Ziekenhuis Leuven)

    Leuven, Belgium · Recruiting

  • CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia

    São Paulo, Brazil · Recruiting

  • CEPON - Centro de Pesquisa Oncologicas de Santa Catarina

    Florianópolis, Santa Catarina, Brazil · Recruiting

  • Centre Hospitalier de l'Université de Montréal (CHUM)

    Québec, Montreal, Canada · Recruiting

  • Sunnybrook Research Institute

    Toronto, Ontario, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.